Serina Therapeutics, Inc. (SER)
SER moved a median of 0.00% 30 minutes after news, and -0.61% by the close. How SER actually reacts to news — the realized, point-in-time move the market made, measured across 275 labeled events over the last three years with zero look-ahead.
SER’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 205 |
| 30-min | 0.00% | 45% | 238 |
| 60-min | +0.20% | 50% | 251 |
| to close | -0.61% | 41% | 266 |
| Middle 50% of SER reactions | -2.30% to +1.91% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 275 |
Half of all Serina Therapeutics, Inc. news events land between -2.30% and +1.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SER moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SER's baseline. Nothing else.
Recent SER events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Serina Therapeutics, For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -2.09% | -3.48% | |
| Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress" | Press release | GlobeNewswire | +0.99% | -2.28% | |
| Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +2.90% | -7.88% | |
| Form 8-K Serina Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -12.73% | -6.54% | |
| Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 | Press release | GlobeNewswire | -12.73% | -6.54% | |
| Form EFFECT Serina Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.83% | +4.17% | |
| Form 8-K Serina Therapeutics, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.45% | |
| Form S-1 Serina Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -4.03% | -1.10% | |
| Form 10-Q Serina Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +6.06% | |
| Form 8-K Serina Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.06% | |
| Form S-8 Serina Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +6.06% | |
| Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.00% | +6.06% | |
| Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference | Press release | GlobeNewswire | +0.00% | -2.82% | |
| Form 8-K Serina Therapeutics, For: Jul 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.82% | |
| Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease | Press release | GlobeNewswire | +1.48% | -3.69% | |
| Form 8-K Serina Therapeutics, For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -3.69% | |
| Serina Therapeutics Appoints Farrell Simon to its Board of Directors | Press release | GlobeNewswire | +1.48% | -3.69% | |
| Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease | Press release | GlobeNewswire | +0.69% | +0.46% | |
| Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program | Press release | GlobeNewswire | +0.00% | +4.30% | |
| Form 8-K Serina Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -2.67% | |
| Form EFFECT Serina Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.69% | +5.68% | |
| Form S-3 Serina Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.00% | -4.00% | |
| Form 10-Q Serina Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.33% | -0.61% | |
| Form 8-K Serina Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +3.33% | -0.61% | |
| Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +3.33% | -0.61% | |
| Form DEFA14A Serina Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.08% | |
| Form DEF 14A Serina Therapeutics, For: Apr 27 | SEC filing · Form DEF | SEC EDGAR | -1.10% | +1.65% | |
| Form 8-K Serina Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | -0.51% | |
| Form PRE 14A Serina Therapeutics, For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | +0.13% | +2.44% | |
| Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit | Press release | GlobeNewswire | -1.79% | +0.00% | |
| Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan | Press release | GlobeNewswire | -2.28% | -1.83% | |
| Form 10-K/A Serina Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.11% | +0.44% | |
| Form 10-K Serina Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.98% | -5.43% | |
| Form 8-K Serina Therapeutics, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | -3.98% | -5.43% | |
| Form S-8 Serina Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.98% | -5.43% | |
| Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -3.98% | -5.43% | |
| Serina Therapeutics to Present at the 38th Annual Roth Conference | Press release | GlobeNewswire | -2.73% | -17.07% | |
| Form 8-K Serina Therapeutics, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -2.73% | -17.07% | |
| Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease | Press release | GlobeNewswire | +8.33% | +18.09% | |
| Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease | Press release | GlobeNewswire | +0.59% | +4.73% | |
| Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease | Press release | GlobeNewswire | -0.89% | +2.98% | |
| Form EFFECT Serina Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +3.28% | -9.84% | |
| Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event | Press release | GlobeNewswire | -2.55% | +0.73% | |
| Form S-3 Serina Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -2.49% | -9.33% | |
| Form 8-K Serina Therapeutics, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -7.81% | |
| Form 8-K Serina Therapeutics, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +3.39% | +13.97% | |
| Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity | Press release | GlobeNewswire | +3.39% | +13.97% | |
| Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry | Press release | GlobeNewswire | +0.00% | -3.70% | |
| Form 8-K Serina Therapeutics, For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | -4.56% | |
| Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program | Press release | GlobeNewswire | +1.29% | -4.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SER section they belong to.
Where else SER is measured.
SER earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Serina Therapeutics, Inc.'s median reaction calculated?
Every labeled SER news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 275 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of SER's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SER's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.